This review explores the intricate relationship between viral infections and Bacillus Calmette-Guerin (BCG) efficacy, emphasizing immune modulation mechanisms that may influence treatment outcomes. Since its introduction in 1976, intravesical BCG has been …

… Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national … the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). They include … Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) SUO-CTC …

… life. A new drug application with the FDA for TAR-200 has … significant portion of bladder cancer patients, currently has limited treatment options after BCG … . 2. New drug application initiated with U.S. FDA for TAR-200 …

Aidixi (disitamab vedotin), an antibody-drug conjugate (ADC) combined with Bacillus Calmette-Guérin (BCG) led to positive efficacy with a manageable safety profile in patients with HER2-expressing, high-risk non–muscle-invasive blader cancer (HR-NMIBC), …

… -node dissection (PLND) for bladder cancer (UBC) might have worse … administration of "any systemic treatment" (OR:0.3 … administration of "any systemic treatment" (OR:0.4 … , and planning future clinical trials. Minerva urology and nephrology. …

Neoadjuvant treatment of bladder cancer is evolving, with … A phase II clinical trial was designed to evaluate … deficiency remained stable throughout treatment and were not predictive … shows therapeutic activity in bladder cancer. Resistance mechanisms seem to …

… outcomes in [patients with bladder cancer] undergoing radical cystectomy, … P <.01). The trial was conducted at 1 … they were restaged after completing treatment. Zaurito P, Longoni … al. Clinical lymphadenopathies in bladder cancer patients staged with 18F …

… the phase 3 BOND-003 trial (NCT04452591), presented at the … BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in … was favorable, with most treatment-related adverse events being low … . These findings support the FDA's prior fast …

… studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that … the phase 3 BOND-003 trial (NCT04452591), have shown a high … from progression to muscle-invasive bladder cancer.  The FDA has granted fast track …

… IIb SunRISe-1 trial (NCT04640623) evaluating the novel bladder cancer treatment TAR-200 (Johnson … bladder, which can sustain local drug exposure over a period of … -granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-high …